Public Sector Pension investment Board lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 50.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,066 shares of the pharmaceutical company’s stock after selling 28,300 shares during the quarter. Public Sector Pension investment Board’s holdings in Vertex Pharmaceuticals were worth $3,617,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. D.A. Davidson & CO. boosted its holdings in Vertex Pharmaceuticals by 1.8% in the second quarter. D.A. Davidson & CO. now owns 24,905 shares of the pharmaceutical company’s stock worth $3,209,000 after acquiring an additional 447 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in Vertex Pharmaceuticals by 153.6% in the second quarter. GSA Capital Partners LLP now owns 19,023 shares of the pharmaceutical company’s stock worth $2,451,000 after acquiring an additional 11,523 shares in the last quarter. Nicholas Investment Partners LP boosted its holdings in Vertex Pharmaceuticals by 0.7% in the second quarter. Nicholas Investment Partners LP now owns 33,000 shares of the pharmaceutical company’s stock worth $4,253,000 after acquiring an additional 214 shares in the last quarter. Rafferty Asset Management LLC boosted its holdings in Vertex Pharmaceuticals by 43.4% in the second quarter. Rafferty Asset Management LLC now owns 17,938 shares of the pharmaceutical company’s stock worth $2,312,000 after acquiring an additional 5,429 shares in the last quarter. Finally, Mutual of America Capital Management LLC boosted its holdings in Vertex Pharmaceuticals by 22.6% in the second quarter. Mutual of America Capital Management LLC now owns 36,203 shares of the pharmaceutical company’s stock worth $4,665,000 after acquiring an additional 6,684 shares in the last quarter. 92.85% of the stock is owned by institutional investors and hedge funds.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at 151.26 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $167.85. The stock has a market capitalization of $38.14 billion, a PE ratio of 145.30 and a beta of 1.75. The stock has a 50 day moving average price of $154.59 and a 200-day moving average price of $128.57.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.06 by $0.33. The business had revenue of $544.10 million during the quarter, compared to analysts’ expectations of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The company’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same period last year, the firm earned $0.24 EPS. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.62 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/24/vertex-pharmaceuticals-incorporated-vrtx-holdings-trimmed-by-public-sector-pension-investment-board.html.

Several equities research analysts have weighed in on the company. Stifel Nicolaus raised their price target on Vertex Pharmaceuticals from $130.00 to $154.00 and gave the stock a “buy” rating in a report on Tuesday, July 18th. Robert W. Baird reissued an “outperform” rating and issued a $171.00 price target (up previously from $136.00) on shares of Vertex Pharmaceuticals in a report on Friday, July 21st. UBS AG downgraded Vertex Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their price target for the stock from $135.00 to $174.00 in a report on Wednesday, July 19th. They noted that the move was a valuation call. Cowen and Company reissued a “market perform” rating and issued a $105.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, July 6th. Finally, J P Morgan Chase & Co set a $175.00 price target on Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-one have assigned a buy rating to the stock. Vertex Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $163.35.

In related news, EVP Stuart A. Arbuckle sold 2,125 shares of Vertex Pharmaceuticals stock in a transaction on Monday, July 31st. The stock was sold at an average price of $152.99, for a total transaction of $325,103.75. Following the completion of the transaction, the executive vice president now directly owns 123,242 shares of the company’s stock, valued at $18,854,793.58. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CMO Jeffrey Chodakewitz sold 3,438 shares of Vertex Pharmaceuticals stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $127.80, for a total value of $439,376.40. Following the transaction, the chief marketing officer now directly owns 125,949 shares of the company’s stock, valued at $16,096,282.20. The disclosure for this sale can be found here. Insiders sold a total of 518,358 shares of company stock valued at $83,072,822 over the last three months. Insiders own 1.80% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.